Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...

Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a medical meeting ...

Amgen plans to proceed with Phase 3 trials, initiating patients on a lower dosage that will gradually increase over an eight-week period.

Amgen's (AMGN) late-stage weight-loss drug MariTide is getting ready to enter the final stages of testing as the company enrolls patients in its phase 3 trial. The company announced Monday that it has ...

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients ...

Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...

Amgen released the long-awaited results from its study of weight loss injection MariTide and the results — while promising — are still being evaluated by industry stakeholders. The pharma giant ...

Two Street analysts weigh in on Amgen's phase 2 MariTide data, saying that they would like to see additional details on the results. Read more here.

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

--Amgen today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide, an investigational antibody peptide conjugate subcutaneously administered monthly or ...